Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Free Report) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock.

A number of other research analysts also recently weighed in on the stock. B. Riley reduced their target price on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Friday, March 14th. D. Boral Capital reissued a "buy" rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $4.20.

Lineage Cell Therapeutics Trading Down 9.9%

Shares of LCTX traded down $0.11 during trading hours on Monday, reaching $0.96. The stock had a trading volume of 3,017,833 shares, compared to its average volume of 1,469,615. The firm has a 50-day simple moving average of $0.62 and a 200 day simple moving average of $0.62. Lineage Cell Therapeutics has a 12 month low of $0.37 and a 12 month high of $1.15. The company has a market capitalization of $220.21 million, a price-to-earnings ratio of -12.05 and a beta of 1.52.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several large investors have recently bought and sold shares of the business. Broadwood Capital Inc. increased its position in Lineage Cell Therapeutics by 18.9% during the first quarter. Broadwood Capital Inc. now owns 49,560,992 shares of the company's stock valued at $22,382,000 after acquiring an additional 7,894,737 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Lineage Cell Therapeutics in the 4th quarter worth approximately $1,984,000. Comerica Bank boosted its holdings in shares of Lineage Cell Therapeutics by 275.0% in the first quarter. Comerica Bank now owns 3,000,000 shares of the company's stock worth $1,355,000 after buying an additional 2,200,000 shares during the last quarter. Renaissance Technologies LLC grew its position in Lineage Cell Therapeutics by 1,058.3% during the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company's stock valued at $1,147,000 after buying an additional 2,085,972 shares during the period. Finally, DAFNA Capital Management LLC increased its holdings in Lineage Cell Therapeutics by 85.9% during the fourth quarter. DAFNA Capital Management LLC now owns 2,511,374 shares of the company's stock valued at $1,262,000 after buying an additional 1,160,666 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.